S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Neovasc Stock Forecast, Price & News

-0.04 (-0.66%)
(As of 07/1/2022 08:00 PM ET)
Today's Range
50-Day Range
52-Week Range
6,500 shs
Average Volume
15,761 shs
Market Capitalization
$16.38 million
P/E Ratio
Dividend Yield
Price Target

Neovasc MarketRank™ Forecast

Analyst Rating
3.00 Rating Score
1,966.1% Upside
$125.00 Price Target
Short Interest
0.14% of Float Sold Short
Dividend Strength
News Sentiment
0.49mentions of Neovasc in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.67 out of 5 stars

Medical Sector

885th out of 1,428 stocks

Surgical & Medical Instruments Industry

90th out of 138 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive NVCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neovasc and its competitors with MarketBeat's FREE daily newsletter.

Neovasc logo

About Neovasc (NASDAQ:NVCN) Stock

Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.

NVCN Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
StockNews.com Begins Coverage on Neovasc (NASDAQ:NVCN)
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Neovasc Comments on European Heart Journal Publication
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$2.55 million
Book Value
$19.31 per share


Free Float
Market Cap
$16.38 million
Not Optionable

Neovasc Frequently Asked Questions

Should I buy or sell Neovasc stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Neovasc stock.
View analyst ratings for Neovasc
or view top-rated stocks.

What is Neovasc's stock price forecast for 2022?

1 equities research analysts have issued 12 month price objectives for Neovasc's stock. Their NVCN stock forecasts range from $125.00 to $125.00. On average, they anticipate Neovasc's stock price to reach $125.00 in the next year. This suggests a possible upside of 1,966.1% from the stock's current price.
View analysts' price targets for Neovasc
or view top-rated stocks among Wall Street analysts.

How has Neovasc's stock price performed in 2022?

Neovasc's stock was trading at $11.7150 at the start of the year. Since then, NVCN stock has decreased by 48.4% and is now trading at $6.05.
View the best growth stocks for 2022 here

When is Neovasc's next earnings date?

Neovasc is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Neovasc

How were Neovasc's earnings last quarter?

Neovasc Inc. (NASDAQ:NVCN) released its quarterly earnings data on Thursday, May, 12th. The medical equipment provider reported ($3.01) EPS for the quarter, missing analysts' consensus estimates of ($1.25) by $1.76. The medical equipment provider earned $0.61 million during the quarter, compared to analyst estimates of $0.80 million. Neovasc had a negative net margin of 1,192.20% and a negative trailing twelve-month return on equity of 50.69%.
View Neovasc's earnings history

When did Neovasc's stock split? How did Neovasc's stock split work?

Neovasc's stock reverse split before market open on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 4 shares after the split.

Who are Neovasc's key executives?

Neovasc's management team includes the following people:
  • Mr. Fredericus A. Colen, Pres, CEO & Director (Age 70, Pay $2.59M)
  • Mr. Christopher Clark B.A., BA (Honours), C.A., CA, PgD, CFO & Corp. Sec. (Age 50, Pay $1.12M)
  • Mr. William Reed Little, Chief Operating Officer (Age 51, Pay $1.2M)
  • Mr. John Christopher Panton, Chief Quality Officer (Age 55, Pay $399.7k)
  • Sarah Marie-Hodgson Gallagher, VP of Clinical Affairs

What other stocks do shareholders of Neovasc own?

What is Neovasc's stock symbol?

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

How do I buy shares of Neovasc?

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neovasc's stock price today?

One share of NVCN stock can currently be purchased for approximately $6.05.

How much money does Neovasc make?

Neovasc (NASDAQ:NVCN) has a market capitalization of $16.38 million and generates $2.55 million in revenue each year. The medical equipment provider earns $-24,890,000.00 in net income (profit) each year or ($12.00) on an earnings per share basis.

How many employees does Neovasc have?

Neovasc employs 49 workers across the globe.

How can I contact Neovasc?

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The official website for Neovasc is www.neovasc.com. The medical equipment provider can be reached via phone at (604) 270-4344, via email at investors@neovasc.com, or via fax at 604-270-4384.

This page (NASDAQ:NVCN) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.